Human Beta-Amyloid (1-42)
Supplier: Anaspec Inc
Removal of any preexisting structures in lyophilized stocks of Aβ-peptide is the critical initial step for controlled aggregation studies. HFIP has been shown to break down β-sheet structure, disrupt hydrophobic forces in aggregated amyloid preparations, and promotes α-helical secondary structure. HFIP treatment of lyophilized Aβ-peptide resulted in a dense, homogeneous preparation of unaggregated peptide and samples can be stored as peptide films. HFIP treated Aβ-peptide samples can be stored as peptide films and can be used in controlled aggregation studies.
Sequence: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Molecular Weight: 4514.1
% Peak Area by HPLC: ≥95
Peptide Content: ≥ 60%
Storage condition: -20°C
Learn more

About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...